Role of Various Imbalances Centered on Alveolar Epithelial Cell/Fibroblast Apoptosis Imbalance in the Pathogenesis of Idiopathic Pulmonary Fibrosis

Role of Various Imbalances Centered on Alveolar Epithelial Cell/Fibroblast Apoptosis Imbalance in the Pathogenesis of Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and age-related lung disease characterized by the histological picture of usual interstitial pneumonia (UIP). It is associated with increased cough, dyspnea, and impaired quality of life, with a median survival of 3 to 5 years from diagnosis. The pathogenesis of IPF has evolved from the belief that chronic inflammation is the direct cause to the understanding that oxidative stress plays a crucial role, and more recently, to the recognition that repetitive micro-injuries and dysfunction of alveolar epithelial cells (AECs) lead to uncontrolled activation and proliferation of fibroblasts, resulting in excessive accumulation of extracellular matrix (ECM). This review explores the complex interactions between environmental, genetic, and epigenetic factors, and the various imbalances centered on AEC/fibroblast apoptosis imbalance in the pathogenesis of IPF.

Environmental, Genetic, and Epigenetic Factors in IPF

The etiology of IPF involves a combination of environmental exposures, genetic predisposition, and epigenetic changes. Environmental exposures, such as cigarette smoking, occupational hazards, infections, and gastroesophageal reflux, are significant contributors to IPF. These exposures affect epigenetic marks, which translate into the regulation of chromatin and shape gene expression profiles. Genetic factors, including mutations in surfactant protein genes (SFTPA1, SFTPA2, SFTPB, SFTPC) and telomere maintenance genes (TERT, TERC), play a crucial role in familial and sporadic IPF. Epigenetic mechanisms, such as DNA methylation, histone modifications, and non-coding RNA (ncRNA) regulation, further dysregulate gene expression in IPF lung tissue.

Endoplasmic Reticulum Stress and Telomere Length Homeostasis

Endoplasmic reticulum (ER) stress is a significant factor in IPF pathogenesis. The accumulation of misfolded proteins in the ER triggers the unfolded protein response (UPR), which, if prolonged, leads to apoptotic cell death. ER stress promotes fibrosis through AEC apoptosis, epithelial-mesenchymal transition (EMT), myofibroblast differentiation, and M2 macrophage polarization. Telomere length homeostasis is also crucial, as telomeres shorten with each cell division. Mutations in telomerase genes result in accelerated telomere shortening, leading to apoptosis or replicative senescence when telomeres reach a critical length.

Mitochondrial Dysfunction and Oxidant/Antioxidant Imbalance

Mitochondrial dysfunction in IPF includes reduced efficiency of the electron transport chain (ETC), excessive production of reactive oxygen species (ROS), decreased mitochondrial biogenesis, and impaired mitophagy. Factors such as telomere shortening, ER stress, oxidative stress, and a profibrotic environment (TGF-β) contribute to mitochondrial dysfunction, which in turn promotes AEC apoptosis and senescence. The oxidant/antioxidant imbalance, known as oxidative stress, is another critical factor in IPF. ROS produced by inflammatory and parenchymal cells amplify the profibrotic TGF-β signaling and promote inflammation, protease/antiprotease imbalance, AEC damage, and fibroblast differentiation.

Inflammation and Immune Response in IPF

Inflammation and immune responses play a significant role in IPF pathogenesis. The Th1/Th2 imbalance, skewed towards a Th2 response, promotes fibrosis through the production of profibrotic cytokines such as IL-4, IL-5, and IL-13. M1-M2 polarization of macrophages, driven by Th2 cytokines, results in excessive production of profibrotic mediators like TGF-β1, PDGF, and TIMP1, which promote fibroblast accumulation and differentiation into myofibroblasts. The protease/antiprotease imbalance, with overexpression of matrix metalloproteinases (MMPs), contributes to fibrosis by promoting EMT, inflammation, and TGF-β signaling.

Plasminogen Activation/Inhibition Imbalance and AEC/Fibroblast Apoptosis Imbalance

The plasminogen activation/inhibition imbalance, with increased expression of plasminogen activator inhibitor 1 (PAI-1), promotes fibrosis by inhibiting plasminogen activators and increasing fibroblast sensitivity to TGF-β. The AEC/fibroblast apoptosis imbalance is central to IPF pathogenesis. Excessive AEC apoptosis leads to alveolar basement membrane destruction and inefficient re-epithelialization, while impaired fibroblast apoptosis results in myofibroblast accumulation and excessive ECM deposition. Factors such as TGF-β, ROS, and FasL promote AEC apoptosis, while increased expression of inhibitors of apoptosis (e.g., survivin, XIAP) protects fibroblasts from apoptosis.

Therapeutic Approaches Based on Complex Pathogenesis

The complexity of IPF pathogenesis necessitates multifaceted therapeutic approaches. Anti-inflammatory and antioxidant therapies have shown limited efficacy, highlighting the need for targeted treatments. Strategies to restore AEC/fibroblast apoptosis balance, such as upregulating miR-29 and miR-30a, and inhibiting XIAP, show promise in preclinical studies. Targeting mitochondrial ROS production and NOX inhibition are potential therapeutic avenues. Future research should focus on treatments that address multiple mechanisms, with the adjustment of AEC/fibroblast apoptosis imbalance as the central focus.

Conclusion

IPF is a multifactorial disease resulting from complex interactions between environmental, genetic, and epigenetic factors. The pathogenesis involves various imbalances, including ER stress, telomere length homeostasis, mitochondrial dysfunction, oxidant/antioxidant imbalance, Th1/Th2 imbalance, M1-M2 polarization of macrophages, protease/antiprotease imbalance, and plasminogen activation/inhibition imbalance. The AEC/fibroblast apoptosis imbalance is central to IPF, as it drives alveolar destruction and fibrosis. Understanding these mechanisms provides a foundation for developing targeted therapies to improve outcomes for patients with IPF.

doi.org/10.1097/CM9.0000000000001288

Was this helpful?

0 / 0